5 High Growth UK Stocks to Buy

3. Vaccitech plc (NASDAQ:VACC)

Q/Q Sales Growth: 32,347%

Number of Hedge Fund Holders in Q4 2022: 3

Vaccitech plc (NASDAQ:VACC) is a biotechnology company developing treatments for hepatitis B, cancer, and other infectious diseases.

For its September 2022 quarter, Vaccitech plc (NASDAQ:VACC)  raked in $6.1 million in revenue, marking for a 32,347% annual growth. Insider Monkey took a look at 943 hedge fund portfolios for 2022’s fourth quarter and found out that 3 had bought the firm’s shares.

Vaccitech plc (NASDAQ:VACC)’s largest investor is Michael Platt and William Reeves’ BlueCrest Capital Mgmt. which owns 543,673 shares that are worth $1.2 million.

Follow Barinthus Biotherapeutics Plc.